Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sermin Guven Mese

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|August 20, 2019
Durable response after discontinuation of nivolumab therapy in the absence of disease progression or toxicity with two advanced NSCLC patientsMesut Yilmaz, Sermin Guven Mese
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|August 7, 2019
Nivolumab-induced lichen planusMesut Yilmaz, Sermin Guven Mese, Ugur Celik
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 4, 2019
An advanced c-MET-amplified NSCLC patient that was treated with crizotinibMesut Yilmaz, Sermin Guven Mese, Ibrahim Cil, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|August 20, 2019
Durable response after discontinuation of nivolumab therapy in the absence of disease progression or toxicity with two advanced NSCLC patientsMesut Yilmaz, Sermin Guven Mese
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|August 7, 2019
Nivolumab-induced lichen planusMesut Yilmaz, Sermin Guven Mese, Ugur Celik
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 4, 2019
An advanced c-MET-amplified NSCLC patient that was treated with crizotinibMesut Yilmaz, Sermin Guven Mese, Ibrahim Cil, et al.
Pageof 1